--- canonical_name: L-Threonine alternate_names: Threonine, L-Thr, Thr, (2S,3R)-2-Amino-3-hydroxybutanoic Acid, L-2-Amino-3-hydroxybutyric Acid canonical_topic: L-Threonine for Health & Longevity short_topic_lc: l_threonine creation_date: 2026-0719-0245 creator_ai_fullname: Opus 4.8 --- # L-Threonine for Health & Longevity
Evidence Review created on 07/19/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Threonine, L-Thr, Thr, (2S,3R)-2-Amino-3-hydroxybutanoic Acid, L-2-Amino-3-hydroxybutyric Acid ## Motivation L-Threonine is one of the nine essential amino acids — the building blocks of protein that the human body cannot make on its own and must obtain from food. Beyond its role in building proteins, it is a major raw material for the protective mucus layer that lines the gut, and the body draws on it to make glycine, a calming signal in the nervous system. These twin roles have drawn interest from people focused on gut health and healthy aging. First identified in the 1930s as the last essential amino acid to be discovered, threonine has long been a staple of animal feed and a well-studied nutrient. In people, small clinical studies during the 1980s and 1990s tested it as a gentle way to ease muscle stiffness, and a recent laboratory study in a tiny worm reported that extra threonine extended the healthy portion of life. This review examines the evidence for and against supplementing with L-Threonine beyond the amount supplied by a normal diet. It looks at what the research shows about the gut, muscles, nervous system, and aging, how much has been tested for safety, and where the current evidence is strong, weak, or still uncertain. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews that discuss L-Threonine or its main biological roles in substantial depth. * [Physiological Functions of Threonine in Animals: Beyond Nutrition Metabolism](https://pubmed.ncbi.nlm.nih.gov/34444752/) - Tang et al., 2021 A broad narrative review of threonine biology that goes past basic nutrition to cover its roles in gut mucus, immune function, and cell signaling — the most comprehensive single overview of why threonine matters beyond protein-building. * [Specific Roles of Threonine in Intestinal Mucosal Integrity and Barrier Function](https://pubmed.ncbi.nlm.nih.gov/21622125/) - Mao et al., 2011 A focused review explaining why the gut consumes such a large share of dietary threonine and how threonine availability shapes the protective mucus barrier — useful context for anyone interested in threonine and gut health. * [Threonine Metabolism and Embryonic Stem Cell Self-Renewal](https://pubmed.ncbi.nlm.nih.gov/24232288/) - Chen & Wang, 2014 A review of the surprising finding that threonine breakdown feeds both biosynthesis and the chemical tagging of DNA-packaging proteins in stem cells, illustrating a link between this amino acid and cellular renewal that motivates longevity interest. * [What No One Tells You About Essential Amino Acid Supplements](https://www.lifeextension.com/wellness/supplements/essential-amino-acid-supplement) - Mike Shea An accessible consumer overview of essential-amino-acid supplements, including threonine, that frames why and when supplementing the essential amino acids may matter for recovery, muscle maintenance, and general health. Note: Fewer than five items are listed because L-Threonine is a niche supplement topic. A search of the priority expert platforms found no dedicated, in-depth coverage from Rhonda Patrick, Peter Attia, Andrew Huberman, or Chris Kresser; the list was not padded with marginally relevant material. ## Grokipedia [Threonine](https://grokipedia.com/page/Threonine) The Grokipedia article provides a structured overview of threonine's chemistry, biosynthesis and metabolism, dietary sources and industrial production, and its biological and health roles, with a section on history and research. ## Examine No dedicated Examine article for L-Threonine was found. ## ConsumerLab No dedicated ConsumerLab article for L-Threonine was found. ## Systematic Reviews A real-time PubMed search for "threonine" with "systematic review OR meta-analysis" was performed; the relevant results below evaluate threonine's dietary requirement and its clinical testing as an anti-stiffness agent. * [Evaluation of Dietary Protein and Amino Acid Requirements: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/40610129/) - Burstad et al., 2025 A systematic review of human protein and individual essential-amino-acid requirements across life stages that explicitly includes threonine; it concludes the evidence base underpinning the current reference intakes is limited, especially outside young adult males. * [Anti-Spasticity Agents for Multiple Sclerosis](https://pubmed.ncbi.nlm.nih.gov/14583932/) - Shakespeare et al., 2003 A Cochrane systematic review of drugs for muscle stiffness in multiple sclerosis (MS, a nerve-damaging autoimmune disease) that includes threonine among the agents assessed; it found the efficacy of all these agents poorly documented, with no firm prescribing recommendation possible. * [Symptomatic Treatments for Amyotrophic Lateral Sclerosis/Motor Neuron Disease](https://pubmed.ncbi.nlm.nih.gov/28072907/) - Ng et al., 2017 A Cochrane overview of symptom treatments for motor neuron disease that judged the effect of L-Threonine (among others) on muscle cramps uncertain because the underlying evidence was very low quality. * [Clinical Effectiveness of Oral Treatments for Spasticity in Multiple Sclerosis: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/12166503/) - Paisley et al., 2002 A systematic review of oral anti-stiffness treatments in multiple sclerosis that concluded the single randomized controlled trial (RCT, a study that randomly assigns participants to treatment or placebo) of threonine did not support its effectiveness. ## Mechanism of Action L-Threonine is an essential amino acid, meaning the body cannot synthesize it and must obtain it from dietary protein. Its health-relevant actions flow from three roles: * **Protein building block:** Threonine is incorporated directly into structural and secreted proteins. It is especially concentrated in mucins — the large gel-forming proteins of the gut's protective mucus layer, of which MUC2 (the main secreted intestinal mucin) is particularly threonine-rich. It is also a component of collagen, elastin, tooth enamel proteins, and antibodies. * **Precursor to glycine:** Threonine can be broken down to glycine, an amino acid that acts as an inhibitory (calming) neurotransmitter in the spinal cord. Boosting spinal glycine signaling is the proposed basis for threonine's tested anti-stiffness effect. Notably, in the human clinical studies, blood and spinal-fluid threonine rose during supplementation but measured glycine did not change, so the precise mechanism of any clinical effect remains uncertain. * **Metabolic substrate:** Threonine catabolism feeds one-carbon and energy metabolism. An important species difference is relevant here: in rodents, the enzyme threonine dehydrogenase (the enzyme that converts threonine toward glycine and acetyl-CoA) is highly active and central to the stem-cell and longevity findings, whereas in humans the corresponding gene is a non-functional pseudogene (an inactive gene copy). In humans, threonine is instead broken down mainly by threonine dehydratase (an enzyme that converts threonine to a compound feeding energy metabolism) and, to a minor degree, threonine aldolase. This difference is a major reason animal findings may not translate directly to people. Competing mechanistic views exist. Proponents of gut and longevity benefits emphasize mucin synthesis and cell-renewal signaling; skeptics note that most supportive data are from animals whose threonine metabolism differs fundamentally from humans, and that in well-nourished people extra threonine may simply be catabolized without added benefit. Key pharmacological-style properties: threonine is a small, water-soluble neutral amino acid absorbed in the small intestine, with roughly 40–60% of a dietary dose extracted by the gut on first pass (largely for mucin synthesis). As a free amino acid it has a short plasma residence (on the order of hours) and is not metabolized by the liver's cytochrome P450 (CYP) drug-metabolizing enzymes; instead it is handled by the dedicated amino-acid enzymes above, with vitamin B6 (pyridoxal phosphate, the active form of vitamin B6) as a cofactor for several of these steps. It is filtered and largely reabsorbed by the kidneys. ## Historical Context & Evolution Threonine was the last of the essential amino acids to be identified, characterized by William Cumming Rose in 1935 during his work defining the amino acids required for growth; it was named for its structural resemblance to the sugar threose. Its original and still-dominant "use" is nutritional — as a dietary essential nutrient and, industrially, as one of the most-produced feed additives in the world, manufactured by bacterial fermentation (using engineered strains of *Escherichia coli* and *Corynebacterium glutamicum*) and added to swine and poultry diets, where it is the second or third limiting amino acid. Interest in threonine for human health optimization arose along three lines. First, in neurology: because threonine is a precursor to the inhibitory neurotransmitter glycine, researchers in the 1980s and 1990s tested oral threonine as a non-sedating way to reduce muscle stiffness in conditions such as multiple sclerosis, hereditary spastic paraparesis (an inherited disorder causing progressive leg stiffness), and motor neuron disease. The actual findings were consistent but modest: several small double-blind studies detected a measurable reduction in clinical stiffness on examination, without meaningful improvement in how patients felt or functioned. These results were neither dramatic enough to enter mainstream practice nor discredited — later systematic reviews described the evidence as limited rather than refuting a genuine effect. Second, in gastroenterology, isotope-tracer work established that the gut is the body's largest consumer of dietary threonine, chiefly for mucin production, prompting interest in threonine for intestinal barrier health. Third, and most recently, a 2022 laboratory study reported that threonine extended healthspan in a worm model by mimicking aspects of dietary restriction, reviving longevity interest. Scientific opinion continues to evolve: the human relevance of the animal longevity and gut findings remains open, precisely because human threonine metabolism differs from the rodent and worm systems in which the strongest signals were seen. ## Expected Benefits The benefits below are framed for health- and longevity-oriented adults considering supplemental L-Threonine beyond dietary intake. For most such individuals, who are already threonine-replete, the human evidence for added benefit is limited and early. ### Low 🟩 #### Reduction of Muscle Spasticity ⚠️ Conflicted Spasticity is involuntary muscle stiffness and overactive reflexes caused by nerve damage. Because threonine is a glycine precursor and glycine dampens spinal reflexes, several small double-blind, placebo-controlled crossover trials tested oral threonine (about 4.5–7.5 g/day) in multiple sclerosis, hereditary spastic paraparesis, and spinal spasticity. They consistently found a small, statistically significant reduction in stiffness on clinical exam (measured by the Ashworth scale, a clinician's rating of muscle tone), but no improvement in patients' own symptoms or function. The evidence is conflicted: objective signs improved while functional benefit did not, and systematic reviews concluded the effect does not translate into clinical usefulness. The signal is genuine but minor, and relevant mainly to people with neurological stiffness rather than to healthy users. **Magnitude:** Roughly a 10% reduction in clinician-rated muscle tone (Ashworth scale) versus placebo; no measurable improvement in function or self-reported symptoms. #### Support of Intestinal Mucin & Gut Barrier The gut extracts roughly 40–60% of dietary threonine on first pass, using most of it to build mucins — the threonine-rich proteins of the protective mucus layer. Animal studies show that threonine adequacy supports goblet-cell numbers (the cells that secrete mucus), mucus production, and barrier integrity, and that requirements rise under intestinal stress. The mechanism is well characterized, but direct evidence that supplementing above adequacy improves gut-barrier outcomes in healthy, well-nourished humans is lacking, so the benefit is inferred largely from animal and mechanistic data. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Healthspan Extension via Ferroptosis Inhibition A 2022 study in the worm *Caenorhabditis elegans* reported that threonine supplementation extended healthspan by reducing ferroptosis (a form of iron-dependent cell death) in a ferritin-dependent manner, appearing to mimic aspects of dietary restriction through stress-response pathways. This is a single invertebrate study; there are no human or even mammalian healthspan data, and human threonine metabolism differs importantly from the worm's, so any longevity relevance to people is purely hypothetical at present. #### Prevention of Diet-Induced Fat Accumulation In mice fed a high-fat diet, threonine supplementation reduced fat deposition, suggesting a possible metabolic effect. This is an isolated rodent finding with no confirming human data, and it is offered here only as a mechanistic signal. #### Immune & Connective-Tissue Protein Support As an essential building block of antibodies, collagen, and elastin, adequate threonine is necessary for immune defense and connective-tissue maintenance. Whether supplementing beyond dietary adequacy provides additional benefit in replete adults is unproven; any advantage would most plausibly appear only where intake or absorption is inadequate. ## Benefit-Modifying Factors * **Baseline threonine adequacy:** The single largest modifier. In adults already meeting the requirement (roughly 15 mg per kg of body weight per day) through dietary protein, additional threonine is likely catabolized without added benefit; benefits are most plausible where intake is low (e.g., very low-protein or restrictive plant-based diets) or losses are high. * **Gastrointestinal condition:** Because the gut is the dominant consumer of threonine, people with high mucin turnover or intestinal stress (e.g., inflammatory bowel disease, gut infections, malabsorption) have elevated threonine demand and may in principle be more responsive — though, as noted in the risks section, timing during active inflammation matters. * **Genetic metabolism:** All humans lack functional threonine dehydrogenase (the gene is a pseudogene), which is why rodent- and worm-based mechanisms may not apply. Variation in threonine dehydratase and in amino-acid transporters could influence individual handling, but no validated pharmacogenetic markers guide threonine dosing. * **Sex-based differences:** Human requirement and kinetic studies have been conducted predominantly in men; sex-specific differences in threonine response or requirement are not well established. * **Age-related considerations:** Older adults, including those at the upper end of the target range, often have lower protein intake and reduced anabolic efficiency, which could increase the relevance of adequate threonine; however, no age-specific supplemental benefit has been demonstrated. ## Potential Risks & Side Effects L-Threonine has a strong safety profile. A controlled human study established a no-observed-adverse-effect level (NOAEL, the highest tested dose without harmful effects) of 12 g/day over four weeks in healthy adult men, well above typical supplemental use. ### Low 🟥 #### Transient, Non-Specific Blood-Marker Elevations In the controlled human dosing study, most anthropometric and biochemical measures were unaffected, but a minor, non-specific rise in liver enzymes (AST and ALT — aspartate and alanine aminotransferase, released when liver or muscle cells are stressed) and creatine kinase (CK, a marker of muscle-cell turnover) appeared at 9 g/day — though, inconsistently, not at the higher 12 g/day dose. The changes were mild and not clearly dose-dependent, suggesting they may be incidental rather than a true threonine effect. Reported adverse events during supplementation were mild to moderate and occurred at random, resolving despite continued dosing. **Magnitude:** Minor, transient elevations in AST/ALT and CK at 9 g/day; no consistent dose-response and no clinical sequelae observed. ### Speculative 🟨 #### Worsening of Active Inflammatory Bowel Disease Flares In a mouse model of colitis (inflammation of the colon), threonine given at the onset of inflammation delayed recovery, reduced goblet-cell counts and mucus-gene expression, and lowered a protective immune signal (interleukin-22). This suggests that timing matters and that supplementing during an active gut inflammatory flare could be counterproductive. The finding is from animals only and has not been tested in humans, but it is a plausible caution for people with active inflammatory bowel disease. #### Gastrointestinal Discomfort at High Doses As with other free amino acids taken in gram quantities, large single doses may cause nausea, bloating, or loose stools through osmotic and digestive effects. This is a general expectation for concentrated amino-acid intake rather than a threonine-specific documented harm. #### Nitrogen Load in Kidney or Liver Impairment All amino acids contribute a nitrogen load that must be processed by the liver and cleared by the kidneys. In people with significant kidney or liver impairment, high supplemental amino-acid intake could in theory add metabolic burden. No threonine-specific harm has been documented, but the concern is mechanistically reasonable in these populations. ## Risk-Modifying Factors * **Kidney or liver impairment:** Reduced capacity to process and clear the nitrogen from amino-acid metabolism raises the theoretical risk of high-dose supplementation; these individuals warrant more caution and monitoring. * **Active inflammatory bowel disease:** Based on animal data, supplementing during an active flare may be counterproductive; risk appears tied to timing relative to inflammation rather than to threonine itself. * **Baseline biomarkers:** Pre-existing elevations in liver enzymes (AST/ALT) or muscle markers (CK) would make the minor, non-specific changes seen with dosing harder to interpret and argue for a baseline check before higher-dose use. * **Sex-based differences:** The human safety trial enrolled only men; whether women differ in tolerability or the minor blood-marker changes is unknown. * **Age-related considerations:** Older adults, including those at the upper end of the target range, more often have reduced kidney function, which modestly increases the relevance of the nitrogen-load consideration at high doses. ## Key Interactions & Contraindications * **Glycine and serine supplements:** Because threonine can be converted toward glycine and shares metabolic links with serine, combining it with these amino acids is additive in the same pathway. Severity: caution/monitor. Consequence: theoretical additive calming/glycinergic effect; no documented harm. * **Central anti-spasticity and sedative drugs (baclofen, tizanidine, diazepam, and other benzodiazepines):** Threonine's proposed glycinergic action could in principle add to central muscle-relaxant or sedative effects. Severity: caution. Consequence: possible additive reduction in muscle tone or sedation; monitor if combined. * **Large neutral amino acids and protein/BCAA supplements (branched-chain amino acids — leucine, isoleucine, valine):** High doses of one amino acid taken with others compete for shared intestinal and cellular transporters, which can blunt absorption of either. Severity: minor. Mitigating action: separate large amino-acid doses by 1–2 hours if absorption matters. * **Vitamin B6 (pyridoxine):** Vitamin B6 (as pyridoxal phosphate) is a cofactor for threonine catabolic enzymes; adequate B6 status supports normal threonine metabolism. Severity: nutritional, not adverse. Consequence: none harmful. * **Over-the-counter medications:** No specific over-the-counter drug interactions are documented for threonine; concurrent use of antacids or common analgesics is not known to interact. * **Populations who should avoid or use caution:** People with significant kidney or liver impairment, those with active inflammatory bowel disease flares, and individuals with rare inborn errors of amino-acid metabolism should approach supplemental threonine cautiously and under medical supervision. There is no established safe supplemental dose in pregnancy or lactation, so caution is warranted there as well. ## Risk Mitigation Strategies * **Start low and increase gradually:** Begin at 0.5–1 g/day and increase over 1–2 weeks toward any target dose. This limits gastrointestinal discomfort (nausea, bloating, loose stools) from concentrated amino-acid intake. * **Take with food and split larger doses:** Dividing doses above ~3 g/day into 2–3 servings taken with meals reduces both gastrointestinal upset and transient spikes in blood amino-acid levels. * **Avoid dosing during active gut inflammation:** Given the animal colitis findings, withhold supplementation during an active inflammatory bowel disease flare to avoid the risk of delayed mucosal recovery; if used for gut support, favor periods of remission. * **Respect the safety ceiling:** Keep intake within the tested range; the human no-observed-adverse-effect level was 12 g/day over four weeks, and there is no evidence of benefit from exceeding it. This mitigates unknown risks of very high loading. * **Screen and monitor in kidney or liver impairment:** In anyone with reduced kidney or liver function, check baseline kidney filtration and liver enzymes before higher-dose use and periodically thereafter, to catch any added metabolic burden from the nitrogen load. * **Check baseline liver and muscle markers before higher-dose use:** A baseline AST/ALT and CK measurement makes the minor, non-specific elevations reported at 9 g/day interpretable and prevents misattributing pre-existing changes to threonine. ## Therapeutic Protocol * **General supplemental dose:** For gut or general use, a standard supplemental range is about 1–4 g/day of free-form L-Threonine, taken with food. This sits comfortably below the tested safety ceiling of 12 g/day. * **Neurological stiffness protocol (clinical context):** The double-blind trials that showed a modest anti-stiffness effect used approximately 4.5–7.5 g/day in divided doses; this higher range was applied by neurology researchers rather than integrative practitioners and is relevant only to people with spasticity under medical care. * **Competing approaches:** Some practitioners target the same glycinergic goal with glycine directly (often 3 g or more before sleep), while others favor obtaining threonine from a high-quality protein diet rather than isolated supplementation. Neither is presented here as the default; the choice depends on the goal (gut support, stiffness, or general adequacy). * **Best time of day:** Timing is flexible. Taking threonine with meals reduces gastrointestinal upset; if the goal is any glycine-related calming effect, an evening dose is a reasonable, though unproven, choice. * **Half-life and dosing frequency:** As a free amino acid, threonine has a short plasma residence (hours) and no depot storage, so splitting into 2–3 daily doses maintains more stable levels than a single large dose; single dosing is acceptable at lower intakes. * **Genetic considerations:** No validated genetic markers (such as those used for other interventions) guide threonine dosing; the universal human loss of threonine dehydrogenase applies to everyone and does not individualize the dose. * **Sex-based differences:** Human dosing data derive mainly from men; no sex-specific dose adjustment is established. * **Age-related considerations:** Older adults, including those at the upper end of the target range, may warrant the lower end of the range and closer attention to kidney function, but no formal age-based protocol exists. * **Baseline biomarkers:** Individuals with low dietary protein intake or documented low plasma threonine are the most rational candidates for supplementation; those already replete have little expected upside. * **Pre-existing conditions:** In kidney disease, liver disease, or active inflammatory bowel disease, protocol choices (lower doses, monitoring, avoiding flares) should be individualized with a clinician. ## Discontinuation & Cycling * **Lifelong vs. short-term:** Threonine is a dietary nutrient rather than a chronic medication; there is no requirement for lifelong use. Supplementation can be short-term (e.g., a trial for a specific goal) or ongoing at low doses, and can be stopped at any time. * **Withdrawal effects:** No withdrawal syndrome is known. Stopping supplemental threonine simply returns intake to dietary levels. * **Tapering:** No taper is needed given the absence of dependence or withdrawal. * **Cycling:** There is no evidence that cycling maintains efficacy or is necessary; continuous low-dose use or as-needed use are both reasonable, and cycling is neither established nor required. ## Sourcing and Quality * **Form:** Choose free-form L-Threonine (the naturally occurring stereoisomer), not the racemic DL-Threonine mixture; supplement-grade and pharmaceutical-grade L-Threonine are widely available as powder or capsules. * **Manufacturing:** Commercial threonine is produced by bacterial fermentation, the same well-established process used for food-grade and feed-grade amino acids; this is a mature, high-purity supply chain. * **Third-party testing:** Look for independent quality verification (USP, NSF, or Informed Choice certification) confirming identity, purity, and freedom from heavy-metal and microbial contamination, since amino-acid powders are otherwise hard to assess by eye. * **Reputable sources:** Established amino-acid and sports-nutrition brands that publish certificates of analysis, and compounding pharmacies for higher-dose clinical use, are the most reliable options; avoid unbranded bulk powders without testing documentation. * **Labeling:** Verify the label specifies "L-Threonine" and the exact amount per serving, and that it is free of unnecessary fillers or proprietary blends that obscure the dose. ## Practical Considerations * **Time to effect:** For neurological stiffness, the trials assessed effects over roughly two-week periods; any gut or general effects have no established timeline in humans and should not be expected to be rapid or dramatic. * **Common pitfalls:** Expecting large or fast benefits (the human effects are modest at best); supplementing during an active gut inflammatory flare against the animal-data caution; and taking large single doses on an empty stomach, which invites gastrointestinal upset. * **Regulatory status:** In the United States, L-Threonine is sold as a dietary supplement and is generally recognized as safe as a food/feed additive; it is not an approved drug for any condition, so all health uses are effectively off-label and self-directed. * **Cost and accessibility:** Threonine is inexpensive and widely available; cost and access are not meaningful barriers. ## Interaction with Foundational Habits * **Sleep:** Indirect, potentially potentiating. Because threonine is a precursor to glycine, and glycine taken before bed has been associated with improved subjective sleep quality, threonine could in theory support sleep — but human studies showed threonine dosing did not measurably raise glycine, so any sleep benefit is unproven. If pursued, an evening dose is the logical timing. * **Nutrition:** Direct. Threonine adequacy is normally met by dietary protein; those on high-quality mixed or animal-protein diets are typically replete, while very low-protein or restrictive plant-based diets may run lower. Adequate vitamin B6 supports threonine metabolism, so overall diet quality matters more than isolated supplementation for most people. * **Exercise:** Indirect, minor. As an essential building block of muscle and connective-tissue proteins, threonine contributes to tissue repair, but there is no evidence that supplementing it (as opposed to adequate total protein) enhances training adaptations; whole-protein intake around exercise is the higher-yield lever. * **Stress management:** Indirect, speculative. Any calming effect would work through the glycine pathway and the same inhibitory neurotransmission implicated in the anti-stiffness studies; this is mechanistically plausible but not demonstrated for stress or mood in humans. ## Monitoring Protocol & Defining Success For typical low-dose use in healthy adults, routine laboratory monitoring is not required, as threonine is a dietary amino acid with a wide safety margin. The tests below are most relevant for higher-dose use (approaching the multi-gram range) or for people with kidney, liver, or gut conditions. Baseline testing (before starting higher-dose use) should establish liver enzymes, muscle and kidney markers, and, where diet adequacy is in question, a plasma amino-acid panel. Ongoing monitoring for higher-dose or higher-risk users is reasonable at roughly 4–8 weeks after starting and then every 6–12 months, or sooner if symptoms arise. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | AST / ALT (liver enzymes) | ≤ 25 U/L | Detect the minor, non-specific liver-enzyme rise reported at higher doses | Conventional upper limit is ~40 U/L; fasting not required; recent intense exercise can raise both | | Creatine kinase (CK) | 40–200 U/L | Screen for the transient muscle-marker elevation seen at 9 g/day | Strongly affected by recent exercise; avoid testing within 48–72 h of hard training | | eGFR | > 90 mL/min/1.73m² | Confirm kidney capacity to clear the nitrogen load before higher-dose use | Estimated glomerular filtration rate — a measure of kidney filtering; track over time in older adults or kidney disease; no fasting needed | | BUN | 10–16 mg/dL | Gauge nitrogen load from amino-acid intake | Blood urea nitrogen — a marker of protein/nitrogen handling; conventional range is wider (~7–20 mg/dL); best interpreted alongside eGFR and hydration status | | Plasma amino-acid panel (threonine) | Within the laboratory reference interval | Confirm adequacy or repletion, especially on low-protein diets | Draw fasting for comparability; pairs well with an overall dietary protein assessment | Qualitative markers of success: * Muscle tone or stiffness (for those using it in a neurological context) — any easing of stiffness * Digestive comfort and stool quality — as a rough proxy for gut tolerance * General energy and well-being * Absence of new gastrointestinal upset at the chosen dose ## Emerging Research * **Ongoing threonine-requirement trial in Crohn's disease:** A recruiting interventional study, [NCT04740541](https://clinicaltrials.gov/study/NCT04740541) ("Threonine Requirement in Adult Males With Crohn's Disease Using IAAO"), is measuring the threonine requirement in men with Crohn's disease (a chronic inflammatory bowel condition) using the indicator amino acid oxidation method (IAAO, a technique that infers an amino acid's requirement from how the body burns a labeled tracer). Enrollment is small (about 10 participants); it could clarify whether gut inflammation raises human threonine needs. * **Completed requirement study in inflammatory bowel disease:** [NCT02423460](https://clinicaltrials.gov/study/NCT02423460) ("Threonine Requirement in IBD Adults and Healthy Adult Controls") enrolled about 86 participants to compare threonine requirements between people with inflammatory bowel disease and healthy controls, directly probing the gut-demand hypothesis in humans. * **Longevity and ferroptosis mechanism:** The worm healthspan finding ([Kim et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36323683/)) opens a future question of whether threonine's apparent dietary-restriction-mimicking and cell-death-limiting effects have any counterpart in mammals; this line could either strengthen the longevity case (if confirmed in higher organisms) or weaken it (given the human loss of the key rodent/worm enzyme). * **Human safety boundary established:** The recent dosing trial ([Matsumoto et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40419835/)) set a human no-observed-adverse-effect level of 12 g/day, providing the safety envelope within which any future efficacy trials could operate; a natural next step is a controlled efficacy study in a human health endpoint rather than a requirement or safety endpoint. * **Gut-barrier translation:** Future work extending the extensive animal mucin data ([Mao et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21622125/)) to human intestinal-barrier outcomes would help resolve whether supplementation above adequacy benefits the gut in people, a direction that could move the current Low/Speculative grades in either direction. ## Conclusion L-Threonine is an essential amino acid that most people already obtain in adequate amounts from a protein-containing diet. Its appeal as a supplement rests on a few distinct roles: it is the main building block of the mucus layer that protects the gut lining, the body draws on it to make a calming nervous-system signal, and it contributes to the proteins that form skin, connective tissue, and immune defenses. The human evidence for taking extra threonine is modest and narrow. The clearest testing comes from small studies in people with muscle stiffness, where it produced a measurable but minor easing of stiffness without changing how people actually felt or functioned. Its promise for gut health and for slowing aging rests mainly on animal and laboratory work that has not yet been confirmed in people. On safety, threonine is reassuring: a controlled human study found that even large daily doses were well tolerated, with only minor and inconsistent changes in blood markers. The main open questions are whether the gut and longevity signals seen in animals apply to humans, and whether people with active bowel inflammation should be cautious. Overall, the evidence base is thin and early, offering a wide safety margin alongside benefits that remain largely unproven for otherwise healthy, well-nourished individuals. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**